Overview

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.
Phase:
Phase 4
Details
Lead Sponsor:
University of Illinois at Chicago
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Cilastatin
Imipenem
Relebactam